Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria
Christine Deutschmann(Universitätsklinik für Frauenheilkunde und Geburtshilfe), Georg Pfeiler(Medical University of Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Daphne Gschwantler‐Kaulich(Medical University of Vienna), Rupert Bartsch(Universitätszahnklinik Wien), Maximilian Marhold(Medical University of Vienna), Carmen Leser(Universitätsklinik für Frauenheilkunde und Geburtshilfe), Michael Seifert(Zimmer Biomet (Germany)), Christian F. Singer(Comprehensive Cancer Center Vienna)
Cited by 11
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
|Annals of Oncology|2022|461
Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice
|Science|2018|422